AU2009265170A1 - Methods, compositions and systems for local delivery of drugs - Google Patents

Methods, compositions and systems for local delivery of drugs Download PDF

Info

Publication number
AU2009265170A1
AU2009265170A1 AU2009265170A AU2009265170A AU2009265170A1 AU 2009265170 A1 AU2009265170 A1 AU 2009265170A1 AU 2009265170 A AU2009265170 A AU 2009265170A AU 2009265170 A AU2009265170 A AU 2009265170A AU 2009265170 A1 AU2009265170 A1 AU 2009265170A1
Authority
AU
Australia
Prior art keywords
composition
loder
poly
drugs
sirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009265170A
Other languages
English (en)
Inventor
Amotz Shemi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silexion Therapeutics Corp
Original Assignee
Silenseed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silenseed Ltd filed Critical Silenseed Ltd
Publication of AU2009265170A1 publication Critical patent/AU2009265170A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
AU2009265170A 2008-06-30 2009-06-28 Methods, compositions and systems for local delivery of drugs Abandoned AU2009265170A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12947708P 2008-06-30 2008-06-30
US61/129,477 2008-06-30
PCT/IB2009/052778 WO2010001325A2 (en) 2008-06-30 2009-06-28 Methods, compositions and systems for local delivery of drugs

Publications (1)

Publication Number Publication Date
AU2009265170A1 true AU2009265170A1 (en) 2010-01-07

Family

ID=41130308

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009265170A Abandoned AU2009265170A1 (en) 2008-06-30 2009-06-28 Methods, compositions and systems for local delivery of drugs

Country Status (8)

Country Link
US (1) US8999945B2 (https=)
EP (1) EP2323630B1 (https=)
JP (1) JP2011526619A (https=)
CN (1) CN102137658A (https=)
AU (1) AU2009265170A1 (https=)
BR (1) BRPI0910198A2 (https=)
IL (1) IL210185A0 (https=)
WO (1) WO2010001325A2 (https=)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2416762A2 (en) * 2009-04-08 2012-02-15 SurModics, Inc. Controlled release devices and methods for delivery of nucleic acids
EP2437684B1 (en) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Anterior segment drug delivery
EP2525778B1 (en) * 2010-01-19 2018-08-01 Polypid Ltd. Sustained-release nucleic acid matrix compositions
WO2013011511A1 (en) 2011-07-18 2013-01-24 Mor Research Applications Ltd. A device for adjusting the intraocular pressure
JP5989780B2 (ja) 2011-09-14 2016-09-07 フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． 眼挿入装置および方法
EP2725103A3 (en) 2011-11-14 2016-01-06 Silenseed Ltd Methods and compositions for treating prostate cancer
US20130122096A1 (en) 2011-11-14 2013-05-16 Silenseed Ltd. Compositions for drug delivery and methods of manufacturing and using same
WO2013086419A1 (en) * 2011-12-09 2013-06-13 California Institute Of Technology Polymer scaffolds and their use in the treatment of vision loss
CN102525935A (zh) * 2012-01-18 2012-07-04 上海交通大学医学院 一种纳米药物载体脑内递送方法
US8889642B2 (en) * 2012-04-19 2014-11-18 Silenseed Ltd. Methods and compositions for RNAi-based cancer treatment
NL2009145C2 (en) * 2012-07-06 2014-01-07 Xeltis B V Implant.
CN102861341B (zh) * 2012-09-29 2015-06-17 张建祥 一种能高效负载核酸类药物的复合纳米载体及其制备方法
RU2652063C2 (ru) 2012-10-26 2018-04-24 Форсайт Вижн5, Инк. Офтальмологическая система для замедленного высвобождения лекарственного средства в глазу
WO2014076703A1 (en) * 2012-11-14 2014-05-22 Silenseed Ltd. Methods and compositions for treating cancer
EP3031921B1 (en) 2012-12-12 2025-03-12 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
US10102441B2 (en) * 2013-02-07 2018-10-16 Vanderbilt University Methods for automatic segmentation of inner ear anatomy in post-implantation CT and applications of same
US9784730B2 (en) 2013-03-21 2017-10-10 University Of Washington Through Its Center For Commercialization Nanoparticle for targeting brain tumors and delivery of O6-benzylguanine
CN104394898B (zh) * 2013-05-02 2017-10-13 卡迪奥诺沃姆有限公司 球囊表面涂层
RU2716420C2 (ru) 2013-06-17 2020-03-11 Те Брод Инститьют Инк. Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
MX374532B (es) 2013-06-17 2025-03-06 Broad Inst Inc Suministro, uso y aplicaciones terapéuticas de los sistemas y composiciones crispr-cas, para actuar sobre trastornos y enfermedades utilizando componentes víricos.
CN105683379A (zh) 2013-06-17 2016-06-15 布罗德研究所有限公司 用于对有丝分裂后细胞的疾病和障碍进行靶向和建模的系统、方法和组合物的递送、工程化和优化
CN103394127A (zh) * 2013-08-02 2013-11-20 苏州市马尔泰新材料有限公司 一种含有中西医药的阴道模具材料
CN103394128A (zh) * 2013-08-02 2013-11-20 苏州市马尔泰新材料有限公司 一种含有川芎的模具材料
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
JP6712948B2 (ja) 2013-12-12 2020-06-24 ザ・ブロード・インスティテュート・インコーポレイテッド 組成物、及びヌクレオチドリピート障害におけるｃｒｉｓｐｒ−ｃａｓ系の使用方法
SG10201804975PA (en) 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
EP3080259B1 (en) 2013-12-12 2023-02-01 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
JP7103750B2 (ja) 2013-12-12 2022-07-20 ザ・ブロード・インスティテュート・インコーポレイテッド ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用
JP2017507946A (ja) * 2014-02-26 2017-03-23 エスリス ゲーエムベーハーｅｔｈｒｉｓ ＧｍｂＨ Ｒｎａを胃腸内投与するための組成物
CN104027848B (zh) * 2014-06-24 2015-10-14 中国人民解放军第四军医大学 一种用于牙周组织的生物支架材料及其制备方法
WO2016009428A1 (en) * 2014-07-14 2016-01-21 Silenseed Ltd. Rna interference compositions targeting heat shock protein 90 and methods of use thereof
WO2016028682A1 (en) 2014-08-17 2016-02-25 The Broad Institute Inc. Genome editing using cas9 nickases
US10912933B2 (en) 2014-08-19 2021-02-09 The Regents Of The University Of California Implants for localized drug delivery and methods of use thereof
WO2016049258A2 (en) 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
US11033659B2 (en) 2014-09-29 2021-06-15 Board Of Regents Of The University Of Nebraska Nanofiber structures and methods of synthesis and use thereof
US20180072815A1 (en) 2014-10-23 2018-03-15 Singh Biotechnology, Llc Single Domain Antibodies Directed Against Intracellular Antigens
US20160115247A1 (en) * 2014-10-23 2016-04-28 Singh Biotechnology, Llc Single domain antibodies directed against intracellular antigens
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
EP3889260A1 (en) 2014-12-12 2021-10-06 The Broad Institute, Inc. Protected guide rnas (pgrnas)
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
EP3234192B1 (en) 2014-12-19 2021-07-14 The Broad Institute, Inc. Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
CA2970370A1 (en) 2014-12-24 2016-06-30 Massachusetts Institute Of Technology Crispr having or associated with destabilization domains
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
AU2016279077A1 (en) 2015-06-18 2019-03-28 Omar O. Abudayyeh Novel CRISPR enzymes and systems
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
TWI906646B (zh) 2015-06-18 2025-12-01 美商博得學院股份有限公司 降低脫靶效應的ｃｒｉｓｐｒ酶突變
WO2017031370A1 (en) 2015-08-18 2017-02-23 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
CN116814590A (zh) 2015-10-22 2023-09-29 布罗德研究所有限公司 Vi-b型crispr酶和系统
EP3368687B1 (en) 2015-10-27 2021-09-29 The Broad Institute, Inc. Compositions and methods for targeting cancer-specific sequence variations
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
US12110490B2 (en) 2015-12-18 2024-10-08 The Broad Institute, Inc. CRISPR enzymes and systems
US10342899B2 (en) 2015-12-19 2019-07-09 Cardiac Pacemakers, Inc. Biologically inert coating for implantable medical devices
US11180759B2 (en) 2016-01-19 2021-11-23 The University Of North Carolina At Chapel Hill Methods and compositions using RNA interference and antisense oligonucleotides for inhibition of KRAS
WO2017127473A1 (en) * 2016-01-19 2017-07-27 The University Of North Carolina At Chapel Hill Methods and compositions using rna interference for inhibition of kras
EP3445853A1 (en) 2016-04-19 2019-02-27 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
AU2017257274B2 (en) 2016-04-19 2023-07-13 Massachusetts Institute Of Technology Novel CRISPR enzymes and systems
KR20260004568A (ko) 2016-04-19 2026-01-08 더 브로드 인스티튜트, 인코퍼레이티드 신규한 crispr 효소 및 시스템
US12031235B2 (en) 2016-04-28 2024-07-09 Amogreentech Co., Ltd. Nanofiber composite membrane for guided bone regeneration, and manufacturing method therefor
EP3471787B1 (en) 2016-06-16 2021-08-18 Cardiac Pacemakers, Inc. Hydrophilization and antifouling of enhanced metal surfaces
CN109642231A (zh) 2016-06-17 2019-04-16 博德研究所 Vi型crispr直向同源物和系统
US12595478B2 (en) 2016-06-29 2026-04-07 The Broad Institute, Inc. Crispr-Cas systems having destabilization domain
WO2018017929A1 (en) * 2016-07-21 2018-01-25 Board Of Regents Of The University Of Nebraska Ring and tubular structures and methods of synthesis and use thereof
US10842912B2 (en) 2016-08-09 2020-11-24 Cardiac Pacemakers, Inc. Functionalized PEG for implantable medical devices
WO2018035387A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
EP4485466A3 (en) 2016-08-17 2025-04-02 The Broad Institute Inc. Novel crispr enzymes and systems
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
CA3038304A1 (en) 2016-09-28 2018-04-05 Board Of Regents Of The University Of Nebraska Nanofiber structures and methods of use thereof
US12499971B2 (en) 2016-09-28 2025-12-16 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
KR101949507B1 (ko) * 2016-11-09 2019-02-18 주식회사 삼양바이오팜 Kras를 표적으로 하는 핵산 함유 약제학적 조성물 및 그 제조방법
JP2020511141A (ja) 2017-03-15 2020-04-16 ザ・ブロード・インスティテュート・インコーポレイテッド 新規Ｃａｓ１３ｂオルソログＣＲＩＳＰＲ酵素及び系
AU2018251801B2 (en) 2017-04-12 2024-11-07 Massachusetts Institute Of Technology Novel type VI CRISPR orthologs and systems
US11591601B2 (en) 2017-05-05 2023-02-28 The Broad Institute, Inc. Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
CN110691586A (zh) 2017-05-24 2020-01-14 思兰斯德有限责任公司 用于癌症免疫疗法的组合物和方法
WO2018227078A1 (en) 2017-06-09 2018-12-13 Board Of Regents Of The University Of Nebraska Nanofiber structures and methods of use thereof
CN110168093B (zh) * 2017-09-12 2023-08-15 中科蓝华(广州)生物医药技术有限公司 一种转染细胞内寄生虫的试剂盒及其应用
EP3684726A4 (en) 2017-09-19 2021-06-30 Board of Regents of the University of Nebraska NANOFIBER STRUCTURES AND METHODS OF USING THEM
WO2019058333A2 (en) * 2017-09-22 2019-03-28 Cochlear Limited BIOACTIVE AGENT DISTRIBUTION
WO2019071054A1 (en) 2017-10-04 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODIFYING THE FUNCTION AND STRUCTURE OF BUCKLES AND / OR CHROMATIN DOMAINS
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
US10968257B2 (en) 2018-04-03 2021-04-06 The Broad Institute, Inc. Target recognition motifs and uses thereof
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
US12421507B2 (en) 2018-08-20 2025-09-23 The Broad Institute, Inc. Methods and compositions for optochemical control of CRISPR-CAS9
US12383652B2 (en) 2018-12-14 2025-08-12 Board Of Regents Of The University Of Nebraska Nanofiber structures and methods of manufacture and use thereof
US12534714B2 (en) 2019-03-18 2026-01-27 The Broad Institute, Inc. Type VII CRISPR proteins and systems
EP3969589A1 (en) * 2019-05-17 2022-03-23 Silenseed Ltd. Compositions and methods for reducing perineural invasion and pain
JP7295559B2 (ja) * 2019-06-03 2023-06-21 国立大学法人 奈良先端科学技術大学院大学 キトサン系複合体組成物及びキトサン系複合体の製造方法
US11338119B2 (en) 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
CN115515657A (zh) 2020-03-20 2022-12-23 加利福尼亚大学董事会 用于局部药物递送的可植入药物递送设备
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
WO2022067197A1 (en) * 2020-09-28 2022-03-31 The Regents Of The University Of California Drug implants containing apalutamide and methods of use thereof
IT202100021779A1 (it) 2021-08-11 2023-02-11 Plasfer S R L Piastrine trasfettate con sirna e loro usi terapeutici
TR2021017752A2 (tr) 2021-11-15 2021-12-21 S D Ue Idari Ve Maliis Dai Bas Genelsekreterlik Transdermal- i̇laç salim özelli̇kli̇ yeni̇li̇kçi̇ nanoli̇fli̇ medi̇kal teksti̇l malzemesi̇ üreti̇m yöntemi̇
CN114381421B (zh) * 2022-02-09 2023-08-15 河北医科大学 溶菌酶诱导的小鼠血管平滑肌细胞炎症模型及其建立方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
JPH09124490A (ja) * 1995-10-27 1997-05-13 Eisai Co Ltd ヌクレオチド含有製剤
US6303374B1 (en) 2000-01-18 2001-10-16 Isis Pharmaceuticals Inc. Antisense modulation of caspase 3 expression
US6852709B2 (en) 2000-05-31 2005-02-08 Johns Hopkins University Biologically useful polyphosphates
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7427394B2 (en) 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US6514193B2 (en) * 2000-11-16 2003-02-04 Microspherix Llc Method of administering a therapeutically active substance
US6812217B2 (en) * 2000-12-04 2004-11-02 Medtronic, Inc. Medical device and methods of use
US20040121348A1 (en) * 2001-10-26 2004-06-24 Ribopharma Ag Compositions and methods for treating pancreatic cancer
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
US20060160759A1 (en) * 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
US20060228404A1 (en) * 2004-03-04 2006-10-12 Anderson Daniel G Compositions and methods for treatment of hypertrophic tissues
EP1604697A1 (en) * 2004-06-09 2005-12-14 J.A.C.C. GmbH Implantable device
CA2583826A1 (en) * 2004-10-22 2006-05-04 Benitec, Inc. Therapeutic rnai agents for treating psoriasis
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
US20100310670A1 (en) * 2005-09-02 2010-12-09 Takeda Pharmaceutical Company Limited Sustained-release microsphere containing short chain deoxyribonucleic acid or short chain ribonucleic acid and method of producing the same
JP5460054B2 (ja) * 2005-11-23 2014-04-02 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 腫瘍形成性ｒａｓ特異的細胞障害性化合物およびその使用法
US8138160B2 (en) 2006-08-03 2012-03-20 Warsaw Orthopedic, Inc. Reagents, methods and systems to suppress pro-inflammatory cytokines
US8936794B2 (en) * 2006-08-25 2015-01-20 The Regents Of The University Of Michigan Conducting polymer nanotube actuators for precisely controlled release of medicine and bioactive molecules
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
WO2008073856A2 (en) 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
US20090149569A1 (en) * 2007-07-19 2009-06-11 Shastri V Prasad Surface engineering of tissue graft materials for enhanced porosity and cell adhesion

Also Published As

Publication number Publication date
US8999945B2 (en) 2015-04-07
IL210185A0 (en) 2011-03-31
BRPI0910198A2 (pt) 2016-01-12
EP2323630A2 (en) 2011-05-25
WO2010001325A2 (en) 2010-01-07
JP2011526619A (ja) 2011-10-13
EP2323630B1 (en) 2014-11-19
CN102137658A (zh) 2011-07-27
US20110195123A1 (en) 2011-08-11
WO2010001325A3 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
US8999945B2 (en) Methods, compositions and systems for local delivery of drugs
Pinese et al. Sustained delivery of siRNA/mesoporous silica nanoparticle complexes from nanofiber scaffolds for long-term gene silencing
EP2591770B1 (en) Compositions for siRNA delivery and methods of manufacturing and using same
ES2871029T3 (es) Dispositivos de liberación de fármacos recargables y procedimientos de uso de los mismos
Martin et al. Surface-modified nanoparticles enhance transurothelial penetration and delivery of survivin siRNA in treating bladder cancer
Lei et al. Development of a gene/drug dual delivery system for brain tumor therapy: potent inhibition via RNA interference and synergistic effects
EP2805713B1 (en) Magnetic nanoparticle-samirna complex and method for preparing same
CA2783001C (en) Sustained-release nucleic acid matrix compositions
RU2668794C2 (ru) Композиция, содержащая инкапсулированный антагомир
CN109311919A (zh) 用于肌肉萎缩症的外显子跳跃寡聚体
CN112368382A (zh) 用于预防和治疗纤维化相关疾病和呼吸系统疾病的双调蛋白基因特异性双链寡核苷酸和包含其的组合物
JP7248614B2 (ja) 避妊具及び関連した器具
WO2013157010A1 (en) Methods and compositions for rnai-based cancer treatment
Kim et al. Tumor-suppressing miR-141 gene complex-loaded tissue-adhesive glue for the locoregional treatment of hepatocellular carcinoma
Meng et al. An injectable miRNA-activated matrix for effective bone regeneration in vivo
WO2021066747A1 (en) Self-administrable and implantable polymeric micro-lance shaped device for controlled and targeted delivery
EP4048157A1 (en) Vaginal drug delivery device
WO2012012541A2 (en) SUSTAINED RELEASE siRNA FOR OCULAR DRUG DELIVERY
WO2024124315A1 (en) Antisense oligonucleotide analogs of mir-29 and uses thereof
CN114983965A (zh) 一种聚多巴胺纳米囊泡递送系统及其制备方法和应用
WO2006123631A1 (ja) Ｒｎａ含有組成物
Cobongela Polymers in drug delivery
CN114127289A (zh) 用于降低嗜神经侵袭和疼痛的组合物和方法
US10006030B2 (en) RNA interference compositions targeting heat shock protein 90 and methods of use thereof
Paulmurugan et al. Biodegradable polymer nanocarriers for therapeutic antisense microRNA delivery in living animals

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period